AlphAIalphai — Financial news for AI agents
theglobeandmail.comSEP 11 min read$ASND

Ascendis Pharma Strikes Global Settlement and Licensing Deal With BioMarin Over YUVIWEL

Ascendis Pharma (ASND) and BioMarin Pharmaceutical settled litigation over YUVIWEL, granting Ascendis a non-exclusive license. BioMarin will receive royalties on YUVIWEL sales until 2030 in specified regions. The deal resolves disputes and allows Ascendis to continue developing navepegritide-related products.

Original reporting
theglobeandmail.com
Published Sep 1, 2026, 9:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Ascendis Pharma Strikes Global Settlement and Licensing Deal With BioMarin Over YUVIWEL — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$ASNDBullishMed
01

Why it matters

The deal clears a legal hurdle, potentially stabilizing Ascendis' share price.

02

Market read

Settlement removes uncertainty, may support Ascendis' valuation.

03

What to watch

BioMarin's waiver of regulatory rights may limit future leverage.

Relevance 7/10Novelty 7/10Timing: today

Background

Ascendis Pharma and BioMarin resolved ongoing litigation over navepegritide products.

Company-level read

Ticker impact

$ASNDBullishHigh confidence
Context

Ascendis Pharma announced a global settlement and licensing deal with BioMarin for YUVIWEL, securing rights and royalty terms.

Expected impact

Potential modest upside as litigation risk is eliminated.

Evidence & confidence

Legal resolution and new royalty stream improve outlook; market may price in reduced risk.

Market effects

Sector

May affect rare disease and endocrine biotech sector by clarifying IP landscape.

Regional

Impacts US and EU biotech markets where Ascendis operates.

Global

Limited to companies involved in similar licensing disputes.

Counterpoint

What could challenge this read

Royalty obligations could weigh on cash flow if sales underperform.

Key entities

  • Company
    Ascendis Pharma

    Biotech firm receiving license.

  • Company
    BioMarin Pharmaceutical Inc.

    Licensor granting rights.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 1
$BMRNMed

Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

BioMarin (BMRN) and Ascendis (ASND) settled global patent disputes over Yuviwel. Ascendis will pay BioMarin royalties: 20% in the U.S. and 18% in the EU, Brazil, and South Korea until 2030. Ascendis also received a license to BioMarin's Yuviwel patents. Both companies will dismiss related lawsuits. Ascendis expects 500M euros in 2026 operating cash flow and 5B euros in 2030 revenue.

yahoo.com2 min
SEP 1
$ASNDMed

Ascendis Pharma (ASND) Clears Yuviwel Patent Fight With Global Licensing Deal

Ascendis Pharma (ASND) and BioMarin Pharmaceutical settled patent disputes over Yuviwel and navepegritide-related products. The deal grants Ascendis a worldwide license to develop and commercialize navepegritide therapies, ending litigation and providing commercial clarity. This removes legal risks and replaces them with royalty obligations on Yuviwel sales until 2030, potentially benefiting Ascendis' rare disease portfolio and investor risk assessments.

simplywall.st2 min
AUG 31
$BMRNMed

Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - BioMarin Pharmaceu

BioMarin (BMRN) and Ascendis (ASND) settled global patent disputes over Yuviwel. Ascendis will pay BioMarin 20% royalties on U.S. sales and 18% on EU, Brazil, and South Korea sales until 2030. Ascendis gains full license to BioMarin's Yuviwel patents. Ascendis expects 500M euros in 2026 operating cash flow and 5B euros in 2030 revenue. Yuviwel Q2 2026 revenue was 8M euros. ASND shares were down 0.21%, BMRN up 3.33% in premarket trading.

benzinga.com2 min